The Food and Drug Administration, in a letter to Novo Nordisk (NVO), said the company’s TV advertisement for Wegovy contains “false or misleading” claims about the drug’s ability to help users lose weight.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Begins DKK 15 Billion Share Buyback, Details Early February Purchases
- Morning Movers: Hims & Hers drops after deciding to stop selling Wegovy copycat
- Hims & Hers says Novo Nordisk lawsuit ‘blatant attack’ on millions of Americans
- Novo Nordisk sues Hims & Hers over Wegovy pill, injection copycats, CNBC reports
- Hims & Hers price target lowered to $21 from $26 at BofA